Phase 1b-2 Evaluation of Mitomycin-C/Capecitabine Chemoradiotherapy with Ipilimumab and Nivolumab for Muscle-Invasive Bladder Cancer
- Trial ID
- 2023-509460-19-00
- Sponsor
- Amsterdam UMC Stichting
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to evaluate the **toxicity** and the feasibility and safety of adding nivolumab and/or ipilimumab to mitomycin-C/capecitabine chemoradiation for the treatment of muscle invasive bladder cancer. Additionally, the study aims to assess the disease-free survival (DFS) and DFS rate with this combination therapy. These objectives are clinically relevant as they aim to determine the potential of a bladder-sparing curative treatment, which could significantly impact patient outcomes by reducing the need for radical cystectomy and preserving bladder function.
Secondary objectives include:
- Assessing overall survival and overall survival rate, which are critical endpoints in determining the long-term efficacy of the treatment.
- Evaluating the response rate to understand the proportion of patients who experience a significant reduction in tumor size.
- Investigating the association between biomarkers in peripheral blood and tumor tissue with autoimmune adverse events, which could provide insights into the mechanisms of treatment-related toxicity.
- Exploring the relationship between biomarkers and treatment efficacy to identify potential predictive markers for treatment response.
- Assessing toxicity to further understand the safety profile of the treatment regimen.
Participants
The clinical trial focuses on participants diagnosed with **muscle invasive bladder cancer**. The study population includes both male and female subjects, aged 18 years and older, who are not considered part of a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their willingness to provide informed consent and their ability to demonstrate adequate organ function. They must have undergone a transurethral biopsy of the bladder tumor and have a histologically-confirmed diagnosis of muscle-invasive T2-T4a, N0-1M0 urothelial cell carcinoma of the bladder. The trial does not specify any particular lifestyle considerations such as diet or physical activity. Participants are required to have a performance status of 0 or 1 on the ECOG Performance Scale and must have a bladder function that is accessible for cystoscopic follow-up. The trial aims to assess the feasibility and safety of adding nivolumab and/or ipilimumab to MMC/capecitabine chemoradiation of the bladder.
Plans and Procedures
The clinical trial is designed to evaluate the **feasibility** and safety of combining **nivolumab** and/or **ipilimumab** with **mitomycin** and **capecitabine** chemoradiotherapy as a bladder-sparing treatment for **muscle invasive bladder cancer**. This is a phase 1b-2 study, structured as a randomized, double-blind, controlled trial. The trial is expected to run from October 2018 to April 2025, with the primary objectives being to assess toxicity and disease-free survival (DFS) rates. The study will also evaluate overall survival and response rates according to RECIST 1.1 criteria.
Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as adequate organ function and a histologically-confirmed diagnosis of muscle-invasive T2-T4a, N0-1M0 urothelial cell carcinoma of the bladder. The screening will include laboratory tests to ensure participants meet specific health parameters. Following the screening, participants will be randomized into treatment groups and will receive either the combination therapy or monotherapy. Follow-up visits will be scheduled to monitor the participants' health, assess treatment efficacy, and record any adverse events. The end-of-study visit will conclude the trial, where final assessments will be made to evaluate the primary and secondary endpoints.
The expected length of participant involvement is approximately 6 years, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include the occurrence of dose-limiting toxicity, withdrawal of consent, or any significant health deterioration that contraindicates continued participation. Participants are required to adhere to specific contraceptive measures during and after the study to prevent pregnancy, given the potential risks associated with the investigational treatments. The trial aims to provide valuable insights into the potential of these therapies to offer a curative approach while preserving bladder function in eligible patients.
Treatment
The clinical trial involves the administration of **Nivolumab**, marketed as OPDIVO, which is a **concentrate for solution for infusion**. The pharmaceutical form is a solution for infusion, with a concentration of 10 mg/mL. The route of administration is via **intravenous infusion**. Nivolumab is a protein-based therapeutic agent, specifically classified under the ATC code L01FF01. The product is manufactured by Bristol-Myers Squibb Pharma EEIG and is not a pediatric formulation. The administration schedule and dosage frequency are determined based on the study protocol, ensuring participant compliance through regular monitoring.
Another experimental medication used in the trial is **Ipilimumab**, marketed as YERVOY. This medication is also a **concentrate for solution for infusion**, with a concentration of 5 mg/mL. It is administered intravenously. Ipilimumab is a protein-based therapeutic agent, classified under the ATC code L01FX04. The manufacturer is Bristol-Myers Squibb Pharma EEIG. The dosing schedule and frequency are specified in the study protocol, with compliance monitored throughout the trial.
The trial also includes the use of **Mitomycin**, marketed as Mitomycine Accord. This medication is provided as a **powder for solution for injection/infusion**. The pharmaceutical form is a solution for injection or infusion, and it is administered via intravenous infusion. Mitomycin is a chemical-based therapeutic agent, classified under the ATC code L01DC03. The product is manufactured by Accord Healthcare B.V. The administration and dosing are conducted according to the study protocol, with participant compliance being closely monitored.
Additionally, **Capecitabine**, marketed as Capecitabine Teva, is used in the trial. It is available in the form of **film-coated tablets** with a dosage of 150 mg. The route of administration is oral. Capecitabine is a chemical-based therapeutic agent, classified under the ATC code L01BC06. The manufacturer is TEVA B.V. The dosing schedule and frequency are outlined in the study protocol, with adherence monitored to ensure compliance.
The trial may also involve non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatments, as specified in the study protocol. The administration of all medications is conducted under strict adherence to the protocol, with regular monitoring to ensure participant safety and compliance.
Efficacy
The efficacy of the clinical trial will be assessed using several primary and secondary endpoints. In the phase Ib study, the primary endpoint is the evaluation of toxicity, which will be scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. The incidence of dose-limiting toxicity (DLT) will be monitored during the first six weeks following the initiation of the combination therapy. In the phase II study, the primary endpoints include **disease-free survival (DFS)** and the disease-free survival rate (DFS-rate).
Secondary endpoints for the trial include overall survival, overall survival rate, response rate according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and toxicity as per CTCAE v4.03. These parameters will be measured and analyzed at specified intervals throughout the study to determine the efficacy of the treatment regimens being tested. The trial aims to assess the feasibility and safety of adding nivolumab and/or ipilimumab to mitomycin-C/capecitabine chemoradiation for bladder cancer treatment.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Be willing and able to provide written informed consent for the trial.
- Be ≥ 18 years of age on day of signing informed consent.
- Wish to preserve their bladder function or be ineligible for cystectomy.
- Must have undergone transurethral biopsy of the bladder tumor, within 35 days of planned treatment commencement. The patient should have a histologically-confirmed diagnosis of muscle-invasive T2-T4a, N0-1M0 urothelial cell carcinoma of the bladder.
- Must have undergone maximal transurethral resection of the bladder tumour, to an extent that is judged as safe by the urologist performing the resection, within 35 days of planned treatment commencement.
- Subjects with tumors of mixed urothelial/non-urothelial cell histology are allowed, but urothelial cell carcinoma must be the predominant histology (>50%). Subjects with predominant or exclusively non-urothelial cell histology are not allowed.
- Have planned for chemoradiotherapy as definitive treatment.
- Have a performance status of 0 or 1 on the ECOG Performance Scale
- Have a bladder function that is accessible for cystoscopic follow up.
- Demonstrate adequate organ function as defined below. All screening labs should be performed within 28 days of registering the patient on the trial. Screening laboratory values must meet the following criteria: - WBCs ≥ 2000/μL - Neutrophils ≥ 1500/μL - Platelets ≥ 100 x 10³/μL - Hemoglobin ≥ 5.5 mmol/l - creatinine clearance (CrCl) ≥ 40 mL/minute (using Cockcroft/Gault formula or better) - AST ≤ 3 x ULN vii) ALT ≤ 3 x ULN - Total Bilirubin ≤ 1.5 x ULN (except for subjects with Gilbert Syndrome a total bilirubin ≤ 50 umol/L) - Albumin ≥ 30 mg/L - Lipase ≤ 1.5 ULN. Subjects with Lipase ≥ 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis. - Amylase ≤ 1.5 ULN. Subjects with Amylase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis.
- Female participants of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registering the patient. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Female participants of childbearing potential should be willing to one highly effective method of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 month after the last dose of study medication Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- Male participants should agree to use condoms starting with the first dose of study therapy through 7 month after the last dose of study therapy.
- Willing to consent to the use of their collected tumor specimen, blood and urine as detailed in the protocol for future scientific research including but not limited to DNA, RNA and protein based biomarker detection.
Exclusion Criteria
- Has DPD deficiency
- Has concurrent extra-vesical (i.e. urethra, ureter or renal pelvis) urothelial cell carcinoma of the urothelium. Patients who have involvement of the prostatic urethra with urothelial cell cancer may be included if the location can be safely incorporated in the radiation field.
- Extensive or multifocal bladder carcinoma in situ (CIS) precluding curative chemoradiotherapy.
- Evidence of distant metastatic disease on a CT or FDG PET/CT chest/abdomen/pelvis performed within 28 days prior to study entry. Up to 3 metastatic lymph nodes in the pelvis (below the common iliac arteries) are allowed, if these can be incorporated in the radiotherapy field.
- Prior pelvic lymphadenectomy
- Prior pelvic radiotherapy
- Has had prior intravenous chemotherapy, targeted small molecule therapy, or radiation therapy for treatment of bladder cancer. Prior intravesical BCG and MMC is permitted.
- Unsuitable for concurrent MMC / capecitabine based ChRT based on pre-existing medical conditions.
- Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of treatment. An exception is fiducials that are aimed at improving positional stability during the radiotherapy treatment course. These are allowed.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy over 10mg daily prednisone (or equivalent) or any other form of immunosuppressive therapy within 14 days prior to registering the patient. Patients with adrenal insufficiency receiving replacement dose steroids are allowed on the trial.
- Has a known history of active TB (Bacillus Tuberculosis)
- Hypersensitivity to nivolumab and/or ipilimumab or any of its excipients.
- Prior or concurrent known additional malignancy of any site unless disease free for 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, Stage T1a well differentiated prostatic carcinoma in men (Gleason = 3+3, PSA <5)
- Has any history of active autoimmune disease, Stevens-Johnson syndrome or Guillain-Barre. Exceptions to this are: a. Patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone b. Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen
- Has known history of, or any evidence of active, non-infectious pneumonitis.
- Has an active infection requiring systemic therapy.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient’s participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
- Has an Human Immunodeficiency Virus (HIV) infection with a PCR detectable viral load.
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
The Netherlands | Not Recruiting | 01 Oct 2018 | — |
Netherlands | — | — | 50 |
Sites & Investigators
Research sites
Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
OPDIVO 10 mg/mL concentrate for solution for infusion. | Test | CONCENTRATE FOR SOLUTION FOR INFUSION | IV INFUSION | — | — | PRD2941372 |
YERVOY 5 mg/ml concentrate for solution for infusion | Test | CONCENTRATE FOR SOLUTION FOR INFUSION | INTRAVENOUS | — | — | PRD2381547 |
Mitomycine Accord 40 mg, poeder voor oplossing voor injectie/infusie | Test | POEDER VOOR OPLOSSING VOOR INJECTIE/INFUSIE | INTRAVENIOUS INFUSION | — | — | PRD5534049 |
Capecitabine Teva 150 mg film-coated tablets. | Test | FILM-COATED TABLETS | ORAL | — | — | PRD3844276 |

